Brief: Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care

Dermata Therapeutics

10/09/2025 13:09

Sept 10 (Reuters) - Dermata Therapeutics Inc DRMA.O:

DERMATA THERAPEUTICS INC: HAS WITHDRAWN ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR XYNGARI WITH U.S. FOOD AND DRUG ADMINISTRATION

DERMATA THERAPEUTICS : PLANS TO LAUNCH ITS INITIAL ACNE KIT IN MIDDLE OF 2026 WITH ADDITIONAL PRODUCT CANDIDATES ANTICIPATED TO FOLLOW

DERMATA THERAPEUTICS : STRATEGIC PIVOT TO PRIORITIZE DEVELOPMENT AND DISTRIBUTION OF OTC PHARMACEUTICAL DERMATOLOGY FOCUSED PRODUCTS

Source text: [ID:n0001493152-25-012952]

Further company coverage: DRMA.O

 ((Reuters.Briefs@thomsonreuters.com;))